Evidence map›Paper›PMID 21932836›Full record

ReviewACS chemical biology2011

Fifty years of diazeniumdiolate research. From laboratory curiosity to broad-spectrum biomedical advances.

Larry K Keefer

Abstract readReview
In one paragraph

Review in ACS chemical biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Structural and Functional Siderophore Remodeling by Enzymatic Delipidation.Angewandte Chemie (International ed. in English) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. PreventingACS applied bio materials · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. ACS chemical biology · 2022
    Article
  11. Article
  12. Role of Nitric Oxide-Releasing Glycosaminoglycans in Wound Healing.ACS biomaterials science & engineering · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Nitric Oxide Therapy for Diabetic Wound Healing.Advanced healthcare materials · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Larry K KeeferLaboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, Maryland 21702, United States.

Funding

Using Diazeniumdiolate Chemistry to Design Nitric Oxide-Based TherapiesZIABC005673 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KEEFER, LARRY K · 2009 to 2015
$5.5M
Intramural NIH HHS
6 · The paper itself

Abstract

Here I show that a "pure" research project, seemingly totally lacking in practical application when it was first published, can years later spark a whole new scientific field with the potential to revolutionize clinical practice. A 1961 publication describing adducts of nitric oxide (NO) with certain nucleophiles attracted little notice at the time, but later work showing that the adducts could be hydrolyzed to regenerate the NO in bioactive form has provided the foundation for a host of biomedical applications. Crucial to the discovery of widely used tools for studying NO's chemical biology as well as for the design of a variety of promising therapeutic advances has been the increasingly detailed understanding of the physicochemical properties of these "diazeniumdiolates" (also known as NONOates).

Indexed as

Azo CompoundsBiomedical ResearchAnimalsHumansNitric OxideProtonsSpectrum AnalysisAzo CompoundsdiazeniumdiolateNitric OxideProtons

Identifiers

PMID21932836
PMCPMC3220281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.